Heart Failure Clinics

Papers
(The TQCC of Heart Failure Clinics is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Hypertrophic Cardiomyopathy in RASopathies40
Exercise-Based Cardiac Rehabilitation Programs in Heart Failure Patients33
Diagnosis and Management of Cardiovascular Involvement in Fabry Disease22
Advanced Heart Failure21
Current Prevalence, Incidence, and Outcomes of Heart Failure with Preserved Ejection Fraction21
Clinical Manifestations of 22q11.2 Deletion Syndrome21
Left Ventricular Assist Device20
Exercise Intolerance in Heart Failure with Preserved Ejection Fraction20
Pathophysiology of Heart Failure with Preserved Ejection Fraction19
Combined Effect of Mediterranean Diet and Aerobic Exercise on Weight Loss and Clinical Status in Obese Symptomatic Patients with Hypertrophic Cardiomyopathy19
Cardiovascular Involvement in mtDNA Disease18
Utilizing Artificial Intelligence to Enhance Health Equity Among Patients with Heart Failure18
Cardiovascular Involvement in Transthyretin Cardiac Amyloidosis18
Inotropes in Patients with Advanced Heart Failure16
The Risk of Sudden Unexpected Cardiac Death in Children16
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia16
Phenomapping Heart Failure with Preserved Ejection Fraction Using Machine Learning Cluster Analysis15
Diagnosis and Management of Cardiovascular Involvement in Friedreich Ataxia15
SGLT2 Inhibitors and Safety in Older Patients15
Clinical Practice Guidelines in Cardio-Oncology15
Spontaneous Coronary Artery Dissection14
Clinical Phenogroups in Heart Failure with Preserved Ejection Fraction14
Congestion in Patients with Advanced Heart Failure14
Obesity and Heart Failure with Preserved Ejection Fraction13
Advances in Machine Learning Approaches to Heart Failure with Preserved Ejection Fraction12
Cardiac Magnetic Resonance Quantification of Structure-Function Relationships in Heart Failure11
Biomarkers in Heart Failure11
Role of Cardiac Rehabilitation After Ventricular Assist Device Implantation11
Utilizing Conversational Artificial Intelligence, Voice, and Phonocardiography Analytics in Heart Failure Care10
Anemia and Management of Heart Failure Patients10
Pathophysiology of Advanced Heart Failure10
Cardiac Amyloidosis10
The Role of New Imaging Technologies in the Diagnosis of Cardiac Amyloidosis10
Hypertension and Heart Failure with Preserved Ejection Fraction9
Mitral and Tricuspid Valves Percutaneous Repair in Patients with Advanced Heart Failure9
The Heart Muscle and Valve Involvement in Marfan Syndrome, Loeys-Dietz Syndromes, and Collagenopathies9
Role of Cardiac Magnetic Resonance Imaging in Heart Failure9
Using Artificial Intelligence to Better Predict and Develop Biomarkers9
Renal Dysfunction and Heart Failure with Preserved Ejection Fraction9
Genetics in Congenital Heart Diseases9
The Role of Cardiovascular MRI in Cardio-Oncology8
Spectrum of National Institutes of Health-Funded Research in Cardio-Oncology8
Intracellular Signaling Pathways Mediating Tyrosine Kinase Inhibitor Cardiotoxicity8
Impact of Coronavirus Disease 2019 Pandemic on Cardiac Arrest and Emergency Care7
Machine Learning in Cardiovascular Imaging7
Myocarditis Following COVID-19 Vaccination7
Advanced Heart Failure in Special Population—Pediatric Age7
SGLT2 Inhibitors in Heart Failure7
Cardiovascular Magnetic Resonance of Myocardial Fibrosis, Edema, and Infiltrates in Heart Failure7
Evaluation and Management of Cardiac Sarcoidosis with Advanced Imaging6
Cardiac Resynchronization Therapy and Cardiac Contractility Modulation in Patients with Advanced Heart Failure6
Renoprotective Effects of SGLT2 Inhibitors6
Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk6
Cardiac Resynchronization Therapy in Patients with Heart Failure6
A Review of Heart Failure in Patients with COVID-196
Valvular Disease and Heart Failure with Preserved Ejection Fraction6
Epidemiology, Pathogenesis, and Clinical Course of Takotsubo Syndrome6
SGLT2 Inhibitors and Peripheral Vascular Events6
Advanced Heart Failure in Special Population6
SGLT2 Inhibitors in Type 2 Diabetes Mellitus5
Impact of COVID-19 on Acute Myocardial Infarction Care5
SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction5
Stage A Heart Failure5
Magnetic Resonance-Based Characterization of Myocardial Architecture5
Right Heart Catheterization in Patients with Advanced Heart Failure5
Management of COVID-19 in Patients with Pulmonary Arterial Hypertension5
Cardiovascular Health Care Implications of the COVID-19 pandemic5
Assessment of Pericardial Disease with Cardiovascular MRI5
The Risk of Sudden Death in Children with Hypertrophic Cardiomyopathy5
T-cell Immunotherapy and Cardiovascular Disease5
Genetics of High-Altitude Pulmonary Edema5
Comprehensive Assessment of Heart Failure with Preserved Ejection Fraction Using Cardiac MRI5
Sleep Disorder and Heart Failure with Preserved Ejection Fraction5
SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction4
Racial, Ethnic, and Gender Disparities in Valvular Heart Failure Management4
Cardiopulmonary Exercise Testing in Pulmonary Arterial Hypertension4
Noncoding RNAs in Pulmonary Arterial Hypertension4
Artificial Intelligence and Mechanical Circulatory Support4
Measuring Myocardial Energetics with Cardiovascular Magnetic Resonance Spectroscopy4
Therapy-Related Clonal Hematopoiesis4
Struggling Between Liver Transplantation and Portopulmonary Hypertension4
Framework for Digital Health Phenotypes in Heart Failure4
Oxygen Therapy in Pulmonary Vascular Disease4
Use and Prognostic Implications of Cardiac Troponin in COVID-194
Heart Failure Preserved Ejection Fraction in Women4
Cardiovascular Magnetic Resonance in Right Heart and Pulmonary Circulation Disorders4
Treatment of Advanced Heart Failure—Focus on Transplantation and Durable Mechanical Circulatory Support4
Echocardiography in Advanced Heart Failure for Diagnosis, Management, and Prognosis4
Telehealth in Heart Failure4
Current Status of Pharmacologic and Nonpharmacologic Therapy in Heart Failure with Preserved Ejection Fraction4
Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction4
0.034334897994995